CDKL5's activity, as measured by phosphorylation of its substrates EB2 and MAP1S, is higher at earlier postnatal stages and reflects an early developmental role consistent with the early onset of CDD. The gene discussed is MAP1S; the disease is craniodiaphyseal dysplasia.